Key result
Brevidil M provides rapid, short-acting, non-toxic neuromuscular blockade for electro-shock therapy.
Key points are not available for this paper at this time.
Answers are grounded in this paper and cite their sources.
May support Brevidil M as short-acting relaxant in electro-shock therapy; leaves open validation in modern randomized trials.
As modification of electro-shock is becoming a routine procedure in every patient undergoing this therapy, it is necessary to find a muscle relaxant, or as it has been commonly called a “curarizing agent,” which will be ideal for this purpose. Ideal should mean no toxicity, rapid onset, short duration and rapid termination of neuro-muscular blocking action.
No takes yet. Share an insight, caveat, or question.
J. J. Danik (1953) studied this question. Brevidil M is investigated as a muscle relaxant for electro-shock therapy to provide a non-toxic agent with rapid onset and short duration of neuromuscular blocking action.
Synapse has enriched 10 related papers. Consider them for comparative context: